Change over period: —
NSE · DCAL
DCAL
-54.3% from the 52-week high · +0.0% above the low
Dishman Carbogen Amcis Ltd. is a manufacturing company, which engages in the provision of outsourcing services for the pharmaceutical industry. The company is headquartered in Ahmedabad, Gujarat and currently employs 1,168 full-time employees. The company went IPO on 2017-09-21. The firm's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The firm assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The firm has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The firm's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.
The short version. DCAL reported revenue of ₹507 crore for Sep 2026, down 22.4% from a year earlier. Net profit was ₹-67 crore (down 203.1% year on year). Return on equity was 1.5% in Mar 2026. Promoter holding was 59.32% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
DCAL trades 54.3% below its 52-week high and 0.0% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹507 cr.
Sep 2026 net profit of ₹-67 cr.
23.2 pts lower than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 507 | 678 | 851 | 720 | 653 | 708 | 716 | 682 |
| Net profit | -67 | -58 | 22 | -13 | 65 | 23 | 43 | 5 |
| Net margin % | -13.2 | -8.5 | 2.6 | -1.8 | 10.0 | 3.3 | 6.0 | 0.7 |
| EPS (₹) | -4.26 | -3.69 | 1.39 | -0.83 | 4.16 | 1.49 | 2.75 | 0.3 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2932 | 2712 | 2616 | 2413 | 2141 | 1912 | 2044 | 2059 |
| Net profit | 97 | 3 | -153 | -30 | 18 | -165 | 180 | 210 |
| Net margin % | 3.3 | 0.1 | -5.9 | -1.2 | 0.8 | -8.6 | 8.8 | 10.2 |
| EPS (₹) | 6.22 | 0.21 | -9.79 | -1.9 | 1.15 | -10.53 | 11.49 | 13.03 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 1.5% in Mar 2026; debt to equity is 0.42.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 1.5 | 0.1 | -2.7 | -0.5 |
| Return on capital % | 2.9 | 2.2 | -0.0 | 0.4 |
| EBITDA margin % | 20.7 | 17.3 | 11.7 | 12.8 |
| Net margin % | 3.3 | 0.1 | -5.8 | -1.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 7.0% | 8.9% |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Down 1.78 pts over 8 quarters.
Up 0.24 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 59.32 | 59.32 | 59.32 | 59.32 | 59.32 | 59.32 | 59.32 | 59.32 | 0.0 |
| FII | 8.75 | 9.49 | 9.93 | 8.07 | 7.66 | 7.45 | 6.86 | 6.97 | -1.78 |
| DII | 1.42 | 1.26 | 1.27 | 1.37 | 1.27 | 1.63 | 2.07 | 1.66 | +0.24 |
| Public | 30.51 | 29.93 | 29.47 | 31.23 | 31.75 | 31.6 | 31.75 | 32.06 | +1.55 |
Mutual fund holdings · Oct 2026
3 schemes hold this stock
3 the month before.
- HSBC Flexi Cap Fund0.57% of NAV
- Motilal Oswal BSE Healthcare ETF0.06% of NAV
- Bandhan BSE Healthcare Index Fund0.06% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for DCAL are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about DCAL
What is the DCAL share price?
DCAL (DCAL) last closed at ₹118.53, down 2.16% on the day. Its 52-week range is ₹121.15 to ₹264.95.
What is the market cap of DCAL?
DCAL has a market capitalisation of about ₹1,901 crore. Its price-to-earnings ratio is 97.4.
How are DCAL's latest results?
DCAL reported revenue of ₹507 crore for Sep 2026, down 22.4% from a year earlier. Net profit was ₹-67 crore (down 203.1% year on year). Return on equity was 1.5% in Mar 2026. Promoter holding was 59.32% in Sep 2026, up 0.00 points over 8 quarters.
Who owns DCAL?
As of Sep 2026, shareholding was: Promoter 59.32%, FII 6.97%, DII 1.66%, Public 32.06%.
How many mutual funds hold DCAL?
3 mutual fund schemes held DCAL in October 2026. That compares with 3 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 12 Sep 2019 · Final Dividend - Rs. 0.2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.